These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23161460)

  • 21. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
    O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
    Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod-associated amenorrhea: a report of three cases.
    Alroughani R
    Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
    Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
    Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
    CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
    [No Abstract]   [Full Text] [Related]  

  • 25. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
    Jander S; Turowski B; Kieseier BC; Hartung HP
    Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

  • 27. [Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].
    Rabasseda X
    Drugs Today (Barc); 2010 Jul; 46 Suppl D():1-14. PubMed ID: 20820453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
    Filippi M
    Nat Rev Neurol; 2011 Feb; 7(2):74-5. PubMed ID: 21297650
    [No Abstract]   [Full Text] [Related]  

  • 29. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumefactive multiple sclerosis and fingolimod.
    Lovera J; Villemarette-Pittman N
    J Neurol Sci; 2014 Sep; 344(1-2):1-2. PubMed ID: 24993468
    [No Abstract]   [Full Text] [Related]  

  • 31. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
    Alroughani R; Almulla A; Lamdhade S; Thussu A
    BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25320259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral fingolimod to treat multiple sclerosis: see your cardiologist first.
    Sato DK; Callegaro D
    Arq Neuropsiquiatr; 2014 Sep; 72(9):651-2. PubMed ID: 25252227
    [No Abstract]   [Full Text] [Related]  

  • 34. Novartis eyes oral MS drug as potential blockbuster.
    Ratner M
    Nat Biotechnol; 2010 Nov; 28(11):1135-6. PubMed ID: 21057464
    [No Abstract]   [Full Text] [Related]  

  • 35. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
    Brinkmann V; Billich A; Baumruker T; Heining P; Schmouder R; Francis G; Aradhye S; Burtin P
    Nat Rev Drug Discov; 2010 Nov; 9(11):883-97. PubMed ID: 21031003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fingolimod for multiple sclerosis: a review for the specialist nurse.
    Harrison K
    Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C; Ruggieri S
    Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.